In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Shire buys Transkaryotic Therapies for $1.57bn

Executive Summary

Shire Pharmaceuticals Group PLC has signed a definitive agreement to purchase Transkaryotic Therapies (TKT; protein replacement therapies for rare genetic diseases) for $1.57bn in cash. Shire will buy TKT's fully diluted shares for $37 each, a 31% premium to the average market price.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register